Header Logo

Katherine Griem

Concepts (153)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
18
2017
391
2.130
Why?
Brachytherapy
10
2017
56
1.470
Why?
Radiation Injuries
3
2012
27
1.090
Why?
Radiotherapy Planning, Computer-Assisted
5
2017
68
0.930
Why?
Radiotherapy, Conformal
5
2011
21
0.920
Why?
Skin
2
2012
99
0.760
Why?
Mastectomy, Segmental
8
2009
34
0.670
Why?
Radiotherapy Dosage
14
2017
116
0.520
Why?
Radiotherapy, Adjuvant
5
2017
49
0.460
Why?
Radiometry
4
2017
41
0.450
Why?
Carcinoma, Ductal, Breast
4
2008
34
0.430
Why?
Prone Position
2
2011
30
0.420
Why?
Thermal Conductivity
1
2012
3
0.410
Why?
Thermography
1
2012
11
0.400
Why?
Radiotherapy, Intensity-Modulated
2
2009
36
0.390
Why?
Lymph Nodes
2
2011
67
0.390
Why?
Breast
3
2010
27
0.370
Why?
Heart
2
2009
54
0.340
Why?
Combined Modality Therapy
12
2010
294
0.340
Why?
Genital Neoplasms, Female
1
2010
14
0.340
Why?
Axilla
2
2008
13
0.330
Why?
Female
25
2012
14520
0.330
Why?
Taxoids
1
2009
10
0.320
Why?
Radiodermatitis
1
2009
4
0.320
Why?
Antineoplastic Agents
2
2009
178
0.310
Why?
Middle Aged
18
2011
8541
0.250
Why?
Humans
31
2017
26260
0.240
Why?
Posture
1
2003
59
0.220
Why?
Adult
17
2011
7516
0.200
Why?
Head and Neck Neoplasms
4
1997
148
0.200
Why?
Carcinoma, Squamous Cell
4
1997
172
0.190
Why?
Aged
15
2011
8595
0.180
Why?
Feasibility Studies
3
2011
199
0.180
Why?
Intraoperative Care
2
2017
36
0.160
Why?
Lymph Node Excision
2
1996
23
0.160
Why?
Radiography
4
2009
594
0.150
Why?
Supine Position
2
2011
20
0.150
Why?
Mice
2
2012
1380
0.150
Why?
Treatment Failure
2
2008
158
0.140
Why?
Retrospective Studies
7
2013
3283
0.140
Why?
Lung
3
2011
148
0.130
Why?
Neoplasm Staging
4
2010
358
0.130
Why?
Animals
2
2012
3551
0.120
Why?
Imaging, Three-Dimensional
2
2006
193
0.110
Why?
Accreditation
1
2013
13
0.110
Why?
Radiation Oncology
1
2013
14
0.110
Why?
Pilot Projects
3
2012
397
0.100
Why?
Body Water
1
2012
3
0.100
Why?
Mice, Hairless
1
2012
3
0.100
Why?
Tomography
1
2012
12
0.100
Why?
Education, Medical, Graduate
1
2013
72
0.100
Why?
Fluorouracil
5
1999
45
0.100
Why?
Physicians
1
2013
105
0.100
Why?
Logistic Models
1
2012
353
0.090
Why?
Iridium Radioisotopes
2
2008
4
0.090
Why?
Electronics
2
2010
9
0.090
Why?
Monte Carlo Method
2
2017
46
0.090
Why?
Clinical Competence
1
2013
227
0.090
Why?
Antineoplastic Combined Chemotherapy Protocols
6
1997
228
0.090
Why?
Treatment Outcome
6
2010
3285
0.090
Why?
Internship and Residency
1
2013
201
0.090
Why?
Disease-Free Survival
3
2007
163
0.090
Why?
Neoplasm Recurrence, Local
6
1996
193
0.080
Why?
Radioisotope Teletherapy
1
1989
1
0.080
Why?
Cisplatin
4
1997
47
0.080
Why?
Contracture
1
2009
14
0.080
Why?
Biomarkers
1
2012
556
0.080
Why?
Neoplasms, Radiation-Induced
1
1989
11
0.080
Why?
Organ Size
1
2009
95
0.080
Why?
Liposarcoma
1
1989
16
0.080
Why?
Heart Ventricles
1
2009
90
0.080
Why?
Lymphatic Metastasis
2
2008
87
0.080
Why?
Thyroid Neoplasms
1
1989
44
0.080
Why?
Rectal Neoplasms
1
1989
14
0.080
Why?
Carcinoma, Lobular
2
2007
21
0.080
Why?
Follow-Up Studies
7
2010
1722
0.080
Why?
Models, Biological
2
2004
292
0.080
Why?
Carcinoma in Situ
1
2007
8
0.070
Why?
Mastectomy
1
1987
37
0.070
Why?
Aged, 80 and over
5
2009
4594
0.070
Why?
Tomography, X-Ray Computed
3
2007
675
0.070
Why?
Cell Division
2
1996
80
0.060
Why?
Electrons
1
2004
16
0.060
Why?
Reference Values
1
2003
189
0.050
Why?
Chemotherapy, Adjuvant
3
1996
79
0.050
Why?
Time Factors
4
1996
1347
0.040
Why?
S Phase
2
1996
10
0.040
Why?
Antimetabolites, Antineoplastic
1
1999
17
0.040
Why?
Tongue Neoplasms
1
1999
19
0.040
Why?
Ventricular Dysfunction, Left
1
1999
40
0.040
Why?
Carcinoma
1
1999
65
0.040
Why?
Antineoplastic Agents, Hormonal
2
1996
15
0.040
Why?
Tamoxifen
2
1996
24
0.040
Why?
Biopsy
2
1996
202
0.040
Why?
Neoplasm Invasiveness
2
1995
89
0.040
Why?
Water
1
2017
25
0.040
Why?
Dose-Response Relationship, Radiation
2
2007
9
0.030
Why?
Mouth Mucosa
1
1996
13
0.030
Why?
Paclitaxel
1
1996
42
0.030
Why?
Cell Count
1
1996
75
0.030
Why?
Cellulitis
1
1996
9
0.030
Why?
Esophageal Neoplasms
1
1997
53
0.030
Why?
Adenocarcinoma
1
1997
139
0.030
Why?
Apoptosis
1
1996
190
0.030
Why?
Immunohistochemistry
1
1996
349
0.030
Why?
Cell Cycle
1
1995
34
0.030
Why?
Male
7
1999
14168
0.030
Why?
Survival Rate
1
1995
315
0.030
Why?
Neoplasms, Second Primary
1
1994
39
0.030
Why?
Postoperative Care
2
1996
127
0.030
Why?
Age Factors
1
1995
744
0.030
Why?
Hodgkin Disease
1
1993
12
0.030
Why?
Safety
1
2010
40
0.020
Why?
Cobalt Radioisotopes
1
1989
3
0.020
Why?
Nasopharyngeal Neoplasms
1
1989
3
0.020
Why?
Anal Canal
1
1989
3
0.020
Why?
Child
2
1993
1326
0.020
Why?
Preoperative Care
1
1989
120
0.020
Why?
Statistics as Topic
1
1987
107
0.020
Why?
Hemibody Irradiation
1
2007
2
0.020
Why?
Random Allocation
1
1987
127
0.020
Why?
United States
1
2013
2043
0.020
Why?
Tumor Burden
1
2007
26
0.020
Why?
Clinical Trials as Topic
1
1987
211
0.020
Why?
Survival Analysis
2
1997
242
0.020
Why?
Equipment Design
1
2006
134
0.020
Why?
Relative Biological Effectiveness
1
2004
5
0.010
Why?
Body Burden
1
2004
7
0.010
Why?
Particle Accelerators
1
2004
7
0.010
Why?
Scattering, Radiation
1
2004
37
0.010
Why?
Models, Statistical
1
2004
122
0.010
Why?
Actuarial Analysis
2
1995
8
0.010
Why?
Computer Simulation
1
2004
178
0.010
Why?
Risk Factors
1
1989
2221
0.010
Why?
Heart Diseases
1
1999
62
0.010
Why?
Infusions, Intravenous
1
1997
50
0.010
Why?
Esophagectomy
1
1997
23
0.010
Why?
Carcinoma, Intraductal, Noninfiltrating
1
1996
11
0.010
Why?
Anti-Inflammatory Agents
1
1996
72
0.010
Why?
Idoxuridine
1
1995
2
0.010
Why?
Mitotic Index
1
1995
4
0.010
Why?
G2 Phase
1
1995
4
0.010
Why?
Bromodeoxyuridine
1
1995
9
0.010
Why?
DNA, Neoplasm
1
1995
20
0.010
Why?
Recurrence
1
1996
288
0.010
Why?
Lymphoma
1
1995
31
0.010
Why?
Kinetics
1
1995
158
0.010
Why?
Regression Analysis
1
1995
249
0.010
Why?
Proportional Hazards Models
1
1995
321
0.010
Why?
Contraindications
1
1994
30
0.010
Why?
Anti-Bacterial Agents
1
1996
362
0.010
Why?
Postoperative Complications
1
1996
825
0.010
Why?
Adolescent
1
1993
2172
0.000
Why?
Griem's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (153)
Explore
_
Co-Authors (10)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_